Skip navigation

Canlyniadau chwilio am the

Yn dangos 91 i 105 o 455 canlyniadau

Deadline for expense claims is approaching

As we approach the end of the financial year, please submit all your outstanding expense claims by Sunday 31 March 2019

The HCPC launches its Corporate Plan 2025-2026

The HCPC has published its Corporate Plan 2025-26, setting out how we will continue to make progress on each of our six strategic priorities over the next year.

HCPC supports recommendations to amend medical entitlements of six HCPC professions

Today, the Health and Care Professions Council (HCPC) responded to NHS England’s consultations around proposals to amend the medical entitlements of six HCPC professions.

Performance review requirements 2023-24 - what to expect

We emailed education providers due their performance review in 2023-24 in late June. Providers who will undergo the process this year (2023-24) will have been given specific requirements and a key contact to work with at the HCPC.

August bank holiday 2023 service availability

The HCPC offices will be closed on Monday 28 August for the summer bank holiday weekend

Performance review requirements 2023-24 - what to expect

We emailed education providers due their performance review in 2023-24 in late June. Providers who will undergo the process this year (2023-24) will have been given specific requirements and a key contact to work with at the HCPC.

Quarterly direct debits available from this summer

We are introducing this change following feedback from registrants that more regular payments would help registrants to spread the cost more evenly across the year.

What our Fitness to practise annual report shows

The level of public concern in our professions remains small, but it is rising

Launch of consultation for the standards of conduct, performance and ethics

Today we have launched a consultation which outlines proposed changes to the Standards of conduct, performance and ethics.

Reclassification of Gabapentin and Pregabalin

From midnight on 1st April 2019, gabapentin and pregabalin will be reclassified as Schedule 3 controlled drugs, under the Misuse of Drugs Regulations (2001), and Class C of the Misuse of Drugs Act (1971)